The focus is on GLP-1s, but there's more to Hims & Hers than one product.Hims & Hers (HIMS -4.12%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.*Stock prices used were end-of-day prices of Jan. 8, 2025. The video was published on Jan. 10, 2025. ...

Hims & Hers (NYSE: HIMS ) stock comes from an interesting business that is capitalizing on the trend of ease of healthcare provision through telehealth. However, I'm not certain that its business model has a durable competitiveOliver Rodzianko is an investment analyst specializing in the technology sector, grounded in timeless value principles. His expertise spans AI, semiconductors, software, and renewable energy, with a focus on companies that demonstrate resilient management and lasting competitive advan ...

Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday.The company, which offers a range of direct-to-consumer treatments for conditions like weight loss, erectile dysfunction and hair loss, is the latest in a string of tech companies that have tried to curry favor with the incoming administration. OpenAI CEO Sam Altman and Meta both announced $1 million donations to the inaugural fund late last year, and Amazon and Apple CEO Tim Cook have also ...

公司背景 - Hims & Hers Health 是一家成立于2017年的远程医疗公司 专注于为 stigmatized conditions 提供药物 无需直接与医生交谈 [3] 投资组合 - Hims & Hers Health 是作者投资组合中最大的持仓 占比15% [3] 作者背景 - 作者曾投资房地产 拥有八处价值超过百万美元的房产 后转向股票投资 [1] - 作者的目标是提供深入且易于理解的企业分析 [1]

核心观点 - Hims & Hers Health (HIMS) 股票近期呈现下跌趋势，主要受到宏观趋势和GLP-1相关新闻的影响，但仍被视为值得关注的成长型股票 [1] 股票表现 - Hims & Hers Health (HIMS) 股票价格在2024年12月18日收盘时下跌了7.67% [1] 市场背景 - 股票价格的下跌与宏观趋势和GLP-1相关新闻有关 [1] 投资建议 - 尽管股票充满噪音，但投资者应关注其潜在的成长性 [1]

One of 2024's best stocks is at an intriguing entry pointHims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss drug craze -- is taking a hit after the Food and Drug Administration (FDA) announced Eli Lilly's (LLY) weight-loss drug shortage was resolved. HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth ...

Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven’t exactly been performing well as of late.There’s no big mystery as to why — the COVID-19 pandemic saw a sudden surge in utilization, but as soon as in-person healthcare services resumed, demand dried up significantly. On top of that, this is a field with no shortage of regulatory and legal risks — while the rap ...

Hims & Hers Health, Inc. (HIMS) has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry’s growth of 5.5%.In the third quarter, the company reported revenues of $401.6 million, reflecting a 77% year-over-year increase. Earnings per share (EPS) of 32 cents met the analyst expectations. The company now boasts over 2 million subscribers, of which more than 50% ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.Hims & Hers Health, Inc. (NYSE: HIMS ) is a San Francisco-based $6.7-billion market cap firm that provides a telehealth solution that links people with qualified doctors in the US, the UK, and throughoutHe leads the investing group Beyond the Wall In ...

Hims & Hers Health, Inc. (NYSE: HIMS ) stock is still substantially undervalued even after a massive YTD rally. A 35% discount looks extremely attractive because HIMS is a very promising business that successfully capitalizes on robust secular trendsComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies p ...